t want to start a new thread
NEW YORK FEB 28, 2008 (Reuters Health) - The addition of
thalidomide to topotecan appears to improve treatment response rates of recurrent epithelial ovarian carcinoma, according to the results of a phase II trial.
Because both agents have antiangiogenic properties, the combination of the two might be more effective than topotecan alone, Dr. Levi S. Downs Jr., of the University of Minnesota, Minneapolis and associates speculated.